Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Procaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 6/20 | 0.55 |
| ▸ | SCN2A known ✓ | Q99250 | 6/20 | 0.55 |
| ▸ | SCN3A known ✓ | Q9NY46 | 6/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | MAOA | P21397 | 3/20 | 0.69 |
| ▸ | HTR3A | P46098 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.55 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25282932 | 0.98 | CYP2D6 (0.65) | CYP2D6HRH3TSHRMAOAHTR3A | |
| SCHEMBL31070925 | 0.86 | MAOA (0.49) | CYP2D6HRH3TSHRMAOAHTR3A | |
| SCHEMBL1568843 | 0.86 | MAOA (0.49) | CYP2D6HRH3TSHRMAOAHTR3A | |
| Hydrochloric Acid SCHEMBL7238288 | 0.84 | ACHE (0.50) | CYP2D6HRH3TSHRMAOAHTR3A | |
| Procaine SCHEMBL1021261 | 0.83 | CYP2D6 (0.94) | CYP2D6HRH3TSHRMAOAHTR3A | |
| Procaine SCHEMBL1022025 | 0.83 | CYP2D6 (0.94) | CYP2D6HRH3TSHRMAOAHTR3A | |
| Procaine SCHEMBL3524 | 0.83 | CYP2D6 (1.00) | CYP2D6HRH3TSHRMAOAHTR3A | |
| Procaine SCHEMBL7639278 | 0.82 | CYP2D6 (0.91) | CYP2D6HRH3TSHRMAOAHTR3A | |
| SCHEMBL174306 | 0.82 | MAOA (0.49) | CYP2D6HRH3TSHRMAOAHTR3A | |
| Procaine SCHEMBL3731588 | 0.82 | BLM (1.00) | CYP2D6HRH3TSHRMAOAHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2370413-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2367797-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011037613-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PGI2 RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| EP-2280696-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | SCN1A 1310/4885SCN2A 2000/4885SCN3A 1925/4885 |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | SCN1A 1083/4885SCN2A 1653/4885SCN3A 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.